Last reviewed · How we verify
bimatoprost 20 µg generation 2
At a glance
| Generic name | bimatoprost 20 µg generation 2 |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bimatoprost 20 µg generation 2 CI brief — competitive landscape report
- bimatoprost 20 µg generation 2 updates RSS · CI watch RSS
- Allergan portfolio CI